Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020-Increasing Uptake of Novel Drug Classes to Drive Market Growth

1

Type 2 Diabetes Therapeutics in Asia-Pacific
Markets to 2020-Increasing Uptake of Novel Drug
Classes to Drive Market Growth

Published By GBI Research
Published November 2014
2
Description


GBI Research, the leading business intelligence
provider, has released its latest research, Type
2 Diabetes Therapeutics in Asia-Pacific Markets
to 2020 Increasing Uptake of Novel Drug Classes
to Drive Market Growth, which provides insights
into type 2 diabetes in the Asia-Pacific (APAC)
markets of China, India, Japan and Australia. The
report estimates the market size for 2013 and
provides a forecast until 2020, and covers
disease epidemiology, treatment algorithms, and
treatment use patterns In 2013, the value of the
type 2 diabetes therapeutics market in APAC
countries was an estimated 6.5 billion, and it
is forecast to grow at a Compound Annual Growth
Rate (CAGR) of 7.1 between 2013 and 2020 to
10.5 billion. This strong growth is due to the
anticipated approval of products in relatively
novel treatment classes, such as Glucagon-Like
Peptide-1 (GLP-1) agonists, Dipeptidyl
Peptidase-4 (DPP-4) inhibitors, and Sodium
Glucose Transporter-2 (SGLT-2) inhibitors, as
well as the growth of the prevalence population
in the APAC region, particularly in India and
China.
3
Description


Scope Information on market size for the three
aesthetic lasers and energy devices market
segments minimally invasive body contouring
devices, non-invasive body contouring devices and
laser resurfacing devices. Annualized sales data
by revenue for the 2006-2020 period and company
share data by revenue for 2013 Annualized sales
data by volume for the 2006-2020 period Coverage
of key geographies Australia, China, India,
Japan and South Korea
4
Description

Reasons to buy Derive actionable insights from
value-volume relationships Analyze value-volume
relationships and provide direction to marketing
and sales strategies Develop market-entry and
market-expansion strategies Identify the key
players best positioned to take advantage of
opportunities in the Asian market
5
Table of Contents

• 1 Table of Contents
• 2 Introduction
• 2.1 Symptoms
• 2.2 Etiology
• 3 Marketed Products
• 4 Type 2 Diabetes Market to 2020 Pipeline
  Products
• 4.1 Overall Pipeline
• 4.2 Pipeline Analysis by Molecule Type
• 5 Market Forecast to 2020
• 5.1 Geographical Markets
• 5.1.1 Asia-Pacific Market

6
Table of Contents

• 6 Deals and Strategic Consolidations
• 6.1 Major Licensing Deals
• 6.1.1 Sepracor Enters into Co-Development
  Agreement with Nycomed
• 7 Appendix
• 7.1 All Pipeline Drugs by Phase
• For inquiry, kindly contact at
  http//www.reportsandintelligence.com/enquire-abou
  t-report/176580
• To check table of contents of the research, Visit
  _at_ http//www.reportsandintelligence.com/type-2-di
  abetes-theratype-2-diabetes-therapeutics-in-asia-p
  acific-to-2020-increasing-uptake-of-novel-drug-cla
  sses-to-drive-growthpeutics-in-asia-pacific-to-202
  0-increasing-uptake-of-novel-drug-classes-market/t
  able-of-contents

7

FOR MORE DETAILS
Visit us at
http//www.reportsandintelligence.com/digest-aesth
etic-lasers-and-energy-devices-2006-to-2020-asia-p
acific-market
Stay With Us
TELEPHONE Direct 1 [phone] Toll Free
1 [phone]E-MAIL sales_at_reportsandintellig
ence.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States